The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients
Diabetes mellitus is a complex disorder that involves multiple pathophysiological defects. As the disease progresses, further functional decline in β-cell is apparent. In most cases, patients on oral antidiabetic therapy will require not only an increase in dose, but also the addition of a second or...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Gadjah Mada
2009-12-01
|
Series: | Indonesian Journal of Pharmacy |
Subjects: | |
Online Access: | http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/533 |
id |
doaj-b81049a4aaca4306bcbc9dbe5d05d344 |
---|---|
record_format |
Article |
spelling |
doaj-b81049a4aaca4306bcbc9dbe5d05d3442020-11-25T01:25:57ZengUniversitas Gadjah MadaIndonesian Journal of Pharmacy2338-94272338-94862009-12-0120422423010.14499/indonesianjpharm0iss0pp224-230The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patientsTri Murti Andayani,0 Mohamed Izham Mohamed Ibrahim, 1Ahmad H. Asdie2Fakultas Farmasi Universitas Gadjah Mada . Discipline of Social & Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia . RSUP Dr Sardjito YogyakartaDiabetes mellitus is a complex disorder that involves multiple pathophysiological defects. As the disease progresses, further functional decline in β-cell is apparent. In most cases, patients on oral antidiabetic therapy will require not only an increase in dose, but also the addition of a second or third oral agent. The aim of this study was to evaluate the effectiveness and safety of triple therapy with sulfonylurea, metformin, and acarbose in patients with poorly controlled glycemia. The study design was a prospective observational study in 49 type 2 diabetic patients followed in Department of Endocrinology RSUP Dr Sardjito Indonesia from May 2007 to September 2008. Patients with hypertension were included if their blood pressure was well controlled with antihypertensive medication. All patients with documented gastrointestinal disease were excluded. At baseline and at 3-month intervals, levels of HbA1C, fasting and postprandial plasma glucose, hypoglycemic episodes, and edverse event were evaluated. Fourty nine patients, 22 men and 27 women, aged 62.84 +7.85 years, diabetes duration of 11.92 +6.09 years were studied. The initial HbA1C level was 8.08 +1.89 % which significantly increased to 8.73 +2.37 % (p<0.05). Only 32.98 % of subjects achieved target value of HbA1C (≤ 7 %). Fasting and post-prandrial plasma glucose values were increased from 160.39 +60.25 mg/dL to 170.71+56.60 mg/dL and 210.31+ 75.88 mg/dL to 218.67 +75.03 mg/dL respectively, but not significantly different. Acarbose was more frequently associated with flatulence (46 %) and abdominal bloating (12 %), metformin with flatulence (12 %), nausea (14 %), diarrhea (2 %) and abdominal discomfort (6 %). In conclusion, combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetic patients with poorly controlled glycemia can cause the additive risk of adverse events.http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/533triple therapyglycemic controltype 2 diabetes mellitus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tri Murti Andayani, Mohamed Izham Mohamed Ibrahim, Ahmad H. Asdie |
spellingShingle |
Tri Murti Andayani, Mohamed Izham Mohamed Ibrahim, Ahmad H. Asdie The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients Indonesian Journal of Pharmacy triple therapy glycemic control type 2 diabetes mellitus |
author_facet |
Tri Murti Andayani, Mohamed Izham Mohamed Ibrahim, Ahmad H. Asdie |
author_sort |
Tri Murti Andayani, |
title |
The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
title_short |
The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
title_full |
The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
title_fullStr |
The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
title_full_unstemmed |
The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
title_sort |
effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients |
publisher |
Universitas Gadjah Mada |
series |
Indonesian Journal of Pharmacy |
issn |
2338-9427 2338-9486 |
publishDate |
2009-12-01 |
description |
Diabetes mellitus is a complex disorder that involves multiple pathophysiological defects. As the disease progresses, further functional decline in β-cell is apparent. In most cases, patients on oral antidiabetic therapy will require not only an increase in dose, but also the addition of a second or third oral agent. The aim of this study was to evaluate the effectiveness and safety of triple therapy with sulfonylurea, metformin, and acarbose in patients with poorly controlled glycemia. The study design was a prospective observational study in 49 type 2 diabetic patients followed in Department of Endocrinology RSUP Dr Sardjito Indonesia from May 2007 to September 2008. Patients with hypertension were included if their blood pressure was well controlled with antihypertensive medication. All patients with documented gastrointestinal disease were excluded. At baseline and at 3-month intervals, levels of HbA1C, fasting and postprandial plasma glucose, hypoglycemic episodes, and edverse event were evaluated. Fourty nine patients, 22 men and 27 women, aged 62.84 +7.85 years, diabetes duration of 11.92 +6.09 years were studied. The initial HbA1C level was 8.08 +1.89 % which significantly increased to 8.73 +2.37 % (p<0.05). Only 32.98 % of subjects achieved target value of HbA1C (≤ 7 %). Fasting and post-prandrial plasma glucose values were increased from 160.39 +60.25 mg/dL to 170.71+56.60 mg/dL and 210.31+ 75.88 mg/dL to 218.67 +75.03 mg/dL respectively, but not significantly different. Acarbose was more frequently associated with flatulence (46 %) and abdominal bloating (12 %), metformin with flatulence (12 %), nausea (14 %), diarrhea (2 %) and abdominal discomfort (6 %). In conclusion, combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetic patients with poorly controlled glycemia can cause the additive risk of adverse events. |
topic |
triple therapy glycemic control type 2 diabetes mellitus |
url |
http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/533 |
work_keys_str_mv |
AT trimurtiandayani theeffectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients AT mohamedizhammohamedibrahim theeffectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients AT ahmadhasdie theeffectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients AT trimurtiandayani effectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients AT mohamedizhammohamedibrahim effectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients AT ahmadhasdie effectofcombinationtherapyofsulfonylureametforminandacarboseintype2diabetesmellituspatients |
_version_ |
1725111595804131328 |